Panoro Energy ASA misses on revenue (OTCMKTS:PESAF)  2020/08/27 12:51:55 Seeking Alpha
Panoro Energy ASA (OTC:PESAF): Q2 GAAP EPS of -$0.07. Revenue of $5.13M (-52.1% Y/Y) misses by $3.87M. Press Release
   Worldwide Brain Aneurysm Treatment Industry to 2027 - Featuring Mizuho Medical, Penumbra & Medtronic Among Others -  2020/08/25 12:01:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Brain Aneurysm Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Condition; End User, and Geography" report has been added to's offering. The brain aneurysm treatment market was valued at US$ 2,184.15 million in 2019 and is expected to grow at a CAGR of 14.1% from 2020 to 2027 to reach US$ 6,222.47 million by 2027. Driving factors of the brain aneurysm treatment market are increasing prevalence of brain aneurysm
   The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal  2020/08/14 12:26:21 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inozyme Pharma Inc (NASDAQ: INZY ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Orthopediatrics Corp (NASDAQ: KIDS ) Penumbra Inc (NYSE: PEN ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) Entera Bio Ltd (NASDAQ: ENTX ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(reacted to its second-quarter results) Lantern Pharma Inc. (NASDAQ: LTRN ) NanoVibronix Inc (NASDAQ: NAOV ) Recro Pharma Inc (NASDAQ: REPH ) Stocks In Focus Novavax Agrees to Supply 60M Doses of Coronavirus Vaccine to U.K. Novavax, Inc. (NASDAQ: NVAX ) said it has signed a term sheet with the U.K. for supplying 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate.
   EMERGING MARKETS-Latam FX up against steady dollar; Upbeat economic data lifts Mexican peso  2020/08/11 19:57:54 Reuters
Mexico's peso rose on Tuesday after data showed industrial output rose in June in a sign of recovery following the coronavirus lockdown, while other Latin American currencies strengthened as the dollar held steady. The peso gained 0.3% as a rebound in manufacturing and construction saw Mexican industrial output rise 17.9% in June from May. But, "while production appears to have strengthened in July, further gains will probably be more muted," warned Capital Economics in a client note. Mexico's coronavirus death toll passed 53,000 on Monday as the government struggles to balance the need to curb the pandemic with re-opening Mexico's battered economy. Early in June, the country's Deputy Health Minister had said that a toll of 60,000 would be a "very catastrophic scenario." Brazil's real firmed as the dollar started to lose momentum as signs of an improving global market outlook saw investors betting on riskier currencies. Minutes from Brazil's latest central bank meeting showed interest rates are close to as low as they can go without destabilizing financial markets, meaning any further reductions will likely be gradual and spaced out over time.
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.